Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Val Warner

Physician Assistant, Medical Layton, UT Physician Assistant

NPI 1366819575 CMS profile 10575194

2121 N 1700 W, Layton, UT 84041

Open in the dashboard

General payments

$50,543

907 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Val Warner of Layton, UT is reported in the CMS Open Payments database as having received $50,543 across 907 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,972 172
2024 General $4,080 170
2023 General $2,637 172
2022 General $20,297 221
2021 General $10,558 172

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Val Warner
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Val Warner were reported at $12,972. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Val Warner Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $10,558 $156 $41–$563 $132
2022 $20,297 $185 $55–$649 $149
2023 $2,637 $199 $58–$717 $160
2024 $4,080 $206 $62–$740 $164
2025 $12,972 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alnylam Pharmaceuticals Inc. $17,656 47 payments
  2. Pfizer Inc. $11,782 46 payments
  3. Biohaven Pharmaceuticals, Inc. $8,469 27 payments
  4. AbbVie, Inc. $4,114 289 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $1,094 11 payments
  6. Novo Nordisk Inc $876 75 payments
  7. Amgen Inc. $665 47 payments
  8. Lilly USA, LLC $599 45 payments
  9. Novartis Pharmaceuticals Corporation $529 30 payments
  10. Axsome Therapeutics, Inc. $421 26 payments
  11. Other $4,339 264 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,975 21 payments
  2. Food and Beverage $13,710 851 payments
  3. Travel and Lodging $7,561 28 payments
  4. Consulting Fee $4,265 5 payments
  5. Education $32 2 payments
Products named General payments · program years 2021–2025
  1. GIVLAARI $16,958 44 payments
  2. NURTEC ODT Primary Care $9,563 38 payments
  3. NURTEC ODT Pain $5,739 29 payments
  4. ZAVZPRET $5,365 17 payments
  5. VRAYLAR $1,644 115 payments
  6. Ozempic $773 68 payments
  7. RYBELSUS $718 63 payments
  8. LINZESS $702 46 payments
  9. UBRELVY $627 44 payments
  10. CREON $607 34 payments
  11. Other $10,195 659 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 116 drugs

Part D claims

5,134

Median for Physician Assistant: 241

Drug cost

$553,672

Median for Physician Assistant: $4,110

Branded share of claims

28%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 94 $103,605
Mounjaro Tirzepatide Brand 54 $71,277
Eliquis Apixaban Brand 63 $43,823
Creon Lipase/Protease/Amylase Brand 12 $42,554
Vraylar Cariprazine Hcl Brand 18 $37,251
Nurtec Odt Rimegepant Sulfate Brand 17 $29,583
Jardiance Empagliflozin Brand 24 $25,605
Myrbetriq Mirabegron Brand 27 $22,028
Xarelto Rivaroxaban Brand 28 $20,606
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 27 $19,646

The 10 drugs with the highest cost, of 116 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 133 billing codes

Paid by Medicare

$68,688

Of which drugs: $7,345

Medicare patients

236

Average age 74

Services billed

9,531

137 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Depression 52%
Diabetes 43%
Chronic kidney disease 41%
Ischemic heart disease 30%
Heart failure 29%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 48 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GIVLAARI
$820 — —
VRAYLAR
$534 18 —
UBRELVY
$171 — —
CREON
$134 12 —
Veozah
$100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 48 with Patron

Records

907 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record